Breaking News

Financial Report: AstraZeneca

August 8, 2014

Integration of BMS assets offsets losses


2Q Revenues: $6.5 billion (+4%)

2Q Earnings: $796 million (+9%)

YTD Revenues: $12.9 billion (+2%)

YTD Earnings: $1.3 billion (-4%)

Comments: Diabetes sales were up 128% following the integration of BMS assets and strong U.S. Farxiga launch. Brilinta sales were up 84% in the quarter to $117 million. Crestor sales were down 2% (CER) to $1.5 million. Symbicort sales were $928 million, up 9% (CER). Nexium sales were down 4% (CER) to $971 million. U.S. revenues were up 8%. Declining sales from brands facing generic competition such as Atacand and Seloken/Toprol-XL were offset by the inclusion of 100% of revenue from the diabetes brands. Revenue in the Rest of World (ROW) was up 1%. Revenue in Europe was flat, with the impact of Seroquel XR declines, competitive pressure for Symbicort and loss of exclusivity for Seroquel IR, Atacand and Merrem.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks